India: BBL acquires biosimilar assets of Viatris in cash and stock transaction

Biocon Biologics (BBL), a subsidiary of India’s largest pharmaceutical company, Biocon, has agreed to acquire the biosimilars assets of American global healthcare company, Viatris, for up to US$3.335bn in cash and stock. Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.  In the transaction, Viatris will receive cash…

You must be a HMI Subscriber to view this content.

Subscribe Now »